Delivery Order SPE2DR25D9239-SPE2DR26FFCH0
- Not listed
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 27, 2026, with a ceiling value of $25,326.56 for supply of JAKAFI 10 mg tablets (60 count), with ultimate completion by March 2, 2026. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceuticals and medical consumables to support military...
- The Defense Logistics Agency issued a $12,663.27 delivery order to DMS Pharmaceutical Group Inc. on March 6, 2026, for JAKAFI 10 mg tablets (60-count units) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to military healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. Place of performance...
- The Defense Logistics Agency issued a $25,326.56 delivery order to DMS Pharmaceutical Group Inc. on March 2, 2026, for JAKAFI 10 mg tablets under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. Place of performance is Park Ridge, Illinois. The order has a firm fixed-price structure with an ultimate completion date of March 3, 2026. The PPV-G GEN V is a Defense Logistics Agency...
- The Defense Logistics Agency issued a $12,603.07 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, on February 25, 2026, for JAKAFI 25 mg tablets (60-count unit). The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products and medical consumables to support Department of Defense healthcare operations...
- The Defense Logistics Agency issued a $12,663.27 delivery order to DMS Pharmaceutical Group Inc. on March 4, 2026, for JAKAFI 10 mg tablets (60-count units) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler....
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 6, 2026, for $50,653.12 (ceiling value) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of JAKAFI 10 mg tablets (60-count). PPV-G GEN V is a Defense Logistics Agency single-award Indefinite Delivery Contract authorizing firm fixed-price delivery orders for pharmaceutical products, biologics, and medical consumables to support Department of Defense military...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 9, 2026, with a ceiling value of $18,516.41 for supply of JAKAFI 5 mg tablets (60 count) under its Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract. DMS Pharmaceutical Group Inc. is a woman-owned small business. Place of performance is Park Ridge, IL. The order is firm fixed price with an ultimate completion date of February 10, 2026. PPV-G GEN V...
- The Defense Logistics Agency awarded a delivery order valued at $12,364.81 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of JAKAFI 10 mg tablets (60-count units). This firm fixed-price delivery order, issued on November 3, 2025, with an ultimate completion date of November 4, 2025, was awarded without set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 17, 2026, for $19,246.77 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of JAKAFI 10 mg tablets (60-count units). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business. Place of...
- <p>The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 24, 2026, for $12,720.92 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of JAKAFI 5 mg tablets (60-count units).</p> <p>DMS Pharmaceutical Group Inc. is a woman-owned small business. Place of performance is Park Ridge, IL. The ultimate completion date is February 25, 2026. The order is firm fixed price with no set-aside designation.</p>
- SPE2DR25D9239Indefinite Delivery Contract
- SPE2DR25D9239-SPE2DR26FFCH0Delivery Order
The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 5, 2026, for $12,663.27 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a single-award indefinite delivery contract for pharmaceutical supply to Department of Defense medical facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. Place of performance is Park Ridge, IL. The delivery order calls for JAKAFI 10 mg tablets (60-count units) on a firm fixed-price basis, with ultimate completion March 6, 2026. The PPV-G GEN V contract, awarded to DMS on November 13, 2025, carries a $499.999 billion ceiling and runs through December 31, 2036, structured as a 30-month base period with three 30-month option periods.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.7k | 3/4/26 |